Genomic Profiling of Mycobacterium tuberculosis Strains, Myanmar

Simple item page
dc.citation.issue11
dc.citation.volume27
dc.contributor.authorAung HL
dc.contributor.authorNyunt WW
dc.contributor.authorFong Y
dc.contributor.authorBiggs PJ
dc.contributor.authorWinkworth RC
dc.contributor.authorLockhart PJ
dc.contributor.authorYeo TW
dc.contributor.authorHill PC
dc.contributor.authorCook GM
dc.contributor.authorAung ST
dc.coverage.spatialUnited States
dc.date.accessioned2023-11-30T21:40:46Z
dc.date.accessioned2024-07-25T06:53:21Z
dc.date.available2021-09-02
dc.date.available2023-11-30T21:40:46Z
dc.date.available2024-07-25T06:53:21Z
dc.date.issued2021-11
dc.description.abstractMultidrug resistance is a major threat to global elimination of tuberculosis (TB). We performed phenotypic drug-susceptibility testing and whole-genome sequencing for 309 isolates from 342 consecutive patients who were given a diagnosis of TB in Yangon, Myanmar, during July 2016‒June 2018. We identified isolates by using the GeneXpert platform to evaluate drug-resistance profiles. A total of 191 (62%) of 309 isolates had rifampin resistance; 168 (88%) of these rifampin-resistant isolates were not genomically related, indicating the repeated emergence of resistance in the population, rather than extensive local transmission. We did not detect resistance mutations to new oral drugs, including bedaquiline and pretomanid. The current GeneXpert MTB/RIF system needs to be modified by using the newly launched Xpert MTB/XDR cartridge or line-probe assay. Introducing new oral drugs to replace those currently used in treatment regimens for multidrug-resistant TB will also be useful for treating TB in Myanmar.
dc.description.confidentialfalse
dc.edition.editionNovember 2021
dc.format.pagination2847-2855
dc.identifier.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/34670644
dc.identifier.citationAung HL, Nyunt WW, Fong Y, Biggs PJ, Winkworth RC, Lockhart PJ, Yeo TW, Hill PC, Cook GM, Aung ST. (2021). Genomic Profiling of Mycobacterium tuberculosis Strains, Myanmar.. Emerg Infect Dis. 27. 11. (pp. 2847-2855).
dc.identifier.doi10.3201/eid2711.210726
dc.identifier.eissn1080-6059
dc.identifier.elements-typejournal-article
dc.identifier.issn1080-6040
dc.identifier.urihttps://mro.massey.ac.nz/handle/10179/71105
dc.languageeng
dc.publisherCenters for Disease Control and Prevention
dc.publisher.urihttps://wwwnc.cdc.gov/eid/article/27/11/21-0726_article
dc.relation.isPartOfEmerg Infect Dis
dc.rights(c) The author/s CC BY 4.0en
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en
dc.subjectMyanmar
dc.subjectMycobacterium tuberculosis
dc.subjectantimicrobial resistance
dc.subjectbacteria
dc.subjectexpanded drug resistance testing
dc.subjectgenomic profiling
dc.subjectnew oral regimens
dc.subjectrespiratory infections
dc.subjectstrains
dc.subjecttuberculosis
dc.subjecttuberculosis and other mycobacteria
dc.subjectDrug Resistance, Bacterial
dc.subjectGenomics
dc.subjectHumans
dc.subjectMicrobial Sensitivity Tests
dc.subjectMyanmar
dc.subjectMycobacterium tuberculosis
dc.subjectRifampin
dc.subjectTuberculosis, Multidrug-Resistant
dc.titleGenomic Profiling of Mycobacterium tuberculosis Strains, Myanmar
dc.typeJournal article
pubs.elements-id449322
pubs.organisational-groupOther
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
449322 PDF.pdf
Size:
1.74 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Journal Articles